A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC)

PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease representing 12-13% of total lung cancers, with median survival <2 years. No targeted therapies have proven effective in SCLC. While most patients respond initially to cytotoxic chemotherapies, resistance rapidly emerges, respo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Gaponova, Anna V., Nikonova, Anna S., Deneka, Alexander, Kopp, Meghan C., Kudinov, Alexander E., Skobeleva, Natalia, Khazak, Vladimir, Ogawa, Luisa S., Cai, Kathy Q., Duncan, Kelly E., Duncan, James S., Egleston, Brian L., Proia, David A., Boumber, Yanis, Golemis, Erica A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5065742/
https://ncbi.nlm.nih.gov/pubmed/27267850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-3068
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados